What is the 13F Pro Quality Score for ERNA?

13F Pro ranks Ernexa Therapeutics Inc. (ERNA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ERNA's current score at https://13fpro.ai/company/ERNA (free sign-up required for the full ranking).

Which hedge funds own the most ERNA stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of ERNA include CITADEL ADVISORS, VANGUARD FIDUCIARY CO, Dauntless Investment Group,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/ERNA as soon as new 13F filings post.

Where does 13F Pro source ERNA data?

All Ernexa Therapeutics Inc. fundamentals and ownership data come directly from SEC EDGAR. Ernexa Therapeutics Inc. files with the SEC under CIK 748592. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ERNA in?

Ernexa Therapeutics Inc. (ERNA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ERNA research updated on 13F Pro?

ERNA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Ernexa Therapeutics Inc.(ERNA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 748592 ERNA stock profile & AI dashboard →

13F Pro Quality Score

10.6/100

Rank #2,907 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why ERNA Scores 11/100

exact factor attribution · 2026-09-11

ERNA's composite is driven by earnings growth, held back by revenue growth and scale. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Earnings growth

+2.2 pts

95th pct

Earnings quality

-1.5 pts

35th pct

Institutional flow

-2.3 pts

5th pct

Shareholder dilution

-2.3 pts

4th pct

Capital efficiency

-4.8 pts

2th pct

Profitability

-6.9 pts

4th pct

Free cash flow

-7.0 pts

4th pct

Scale

-7.2 pts

2th pct

Revenue growth

-9.6 pts

2th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

ERNA Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Ernexa Therapeutics Inc. (ERNA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ERNA at 10.6/100 on a 32-signal composite quality model, placing it at rank #2,907 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Ernexa Therapeutics Inc. reports net income of $-4.0M, free cash flow of $-4.2M. Top institutional holders of ERNA by reported 13-F value include CITADEL ADVISORS, VANGUARD FIDUCIARY, Dauntless Investment Group, based on the most recent SEC filings. ERNA trades on the Nasdaq exchange and files with the SEC under CIK 748592. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ERNA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Ernexa Therapeutics Inc. directly from SEC EDGAR. Ernexa Therapeutics Inc.'s 13F Pro composite quality score has ranged between 8 and 12 since 2026, currently 10.6 — a stable long-term trajectory across 8 quarterly and live scoring snapshots.

Net Income

Q2 2026

$-4.0M

Free Cash Flow

Q2 2026

$-4.2M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

—FY 2025

FY22 $0.00FY23 $68.0KFY24 $582.0KFY25 —

Net Income

+68.4% YoY

$-14.1MFY 2025

FY22 $-24.6MFY23 $-21.7MFY24 $-44.5MFY25 $-14.1M

Operating Income

+40.5% YoY

$-9.3MFY 2025

FY22 $-33.2MFY23 $-21.1MFY24 $-15.7MFY25 $-9.3M

EPS (Diluted)

+95.4% YoY

$-2.24FY 2025

FY22 $-8.06FY23 $-4.08FY24 $-48.96FY25 $-2.24

Total Assets

+10.7% YoY

$5.8MFY 2025

FY22 $22.3MFY23 $49.1MFY24 $5.3MFY25 $5.8M

Total Debt

—FY 2025

FY22 —FY23 —FY24 —FY25 —

Op. Cash Flow

+55.7% YoY

$-7.0MFY 2025

FY22 $-21.0MFY23 $-20.4MFY24 $-15.8MFY25 $-7.0M

Free Cash Flow

+56.5% YoY

$-7.1MFY 2025

FY22 $-21.3MFY23 $-20.4MFY24 $-16.2MFY25 $-7.1M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	—	$582.0K +755.9%	$68.0K	$0.00	—	$5.8M
Net Income	$-14.1M +68.4%	$-44.5M -105.6%	$-21.7M +11.8%	$-24.6M +79.9%	$-122.5M -1580.8%	$-7.3M
Operating Income	$-9.3M +40.5%	$-15.7M +25.8%	$-21.1M +36.4%	$-33.2M +70.8%	$-113.7M -1469.2%	$-7.2M
EPS (Diluted)	$-2.24 +95.4%	$-48.96 -1100.0%	$-4.08 +49.4%	$-8.06 -184.8%	$-2.83 -590.2%	$-0.41
Total Assets	$5.8M +10.7%	$5.3M -89.3%	$49.1M +120.5%	$22.3M -29.3%	$31.5M +144.3%	$12.9M
Total Debt	—	—	—	—	—	$2.0M
Operating Cash Flow	$-7.0M +55.7%	$-15.8M +22.4%	$-20.4M +2.7%	$-21.0M +10.7%	$-23.5M -189.9%	$-8.1M
Free Cash Flow	$-7.1M +56.5%	$-16.2M +20.7%	$-20.4M +4.0%	$-21.3M +10.0%	$-23.6M -190.4%	$-8.1M

Get alerted when ERNA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Ernexa Therapeutics Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ERNA

CITADEL ADVISORS LLC
$100.4K15,104 sh
VANGUARD FIDUCIARY TRUST CO
$55.4K8,336 sh
Dauntless Investment Group, LLC
$39.9K6,000 sh
VANGUARD CAPITAL MANAGEMENT LLC
$37.8K5,684 sh
Tradewinds Capital Management, LLC
$2.4K361 sh
BlackRock, Inc.
$219.0033 sh
ASSETMARK, INC
$33.005 sh
SBI Securities Co., Ltd.
$7.001 sh
BNP PARIBAS FINANCIAL MARKETS
$7.001 sh
Steward Partners Investment Advisory, LLC
$1.000 sh

Fund	Value	Shares
CITADEL ADVISORS LLC	$100.4K	15,104
VANGUARD FIDUCIARY TRUST CO	$55.4K	8,336
Dauntless Investment Group, LLC	$39.9K	6,000
VANGUARD CAPITAL MANAGEMENT LLC	$37.8K	5,684
Tradewinds Capital Management, LLC	$2.4K	361
BlackRock, Inc.	$219.00	33
ASSETMARK, INC	$33.00	5
SBI Securities Co., Ltd.	$7.00	1
BNP PARIBAS FINANCIAL MARKETS	$7.00	1
Steward Partners Investment Advisory, LLC	$1.00	0

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ERNA on your watchlist

Track score changes the day Ernexa Therapeutics Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ERNA a good stock to buy?

13F Pro's AI-powered analysis of Ernexa Therapeutics Inc. (ERNA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ERNA are available on the ERNA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ERNA is classified as a small company.

Which hedge funds own ERNA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ERNA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Ernexa Therapeutics Inc.'s investment landscape.